Literature DB >> 18435932

Human alpha-defensins inhibit Clostridium difficile toxin B.

Torsten Giesemann1, Gregor Guttenberg, Klaus Aktories.   

Abstract

BACKGROUND & AIMS: Clostridium difficile toxins A and B are major virulence factors implicated in pseudomembranous colitis and antibiotic-associated diarrhea. The toxins are glucosyltransferases, which inactivate Rho proteins involved in cellular signaling. Human alpha-defensins as part of the innate immune system inactivate various microbial pathogens as well as specific bacterial exotoxins. Here, we studied the effects of alpha-defensins human neutrophil protein (HNP)-1, HNP-3, and enteric human defensin (HD)-5 on the activity of C difficile toxins A and B.
METHODS: Inactivation of C difficile toxins by alpha-defensins in vivo was monitored by microscopy, determination of the transepithelial resistance of CaCo-2 cell monolayers, and analysis of the glucosylation of Rac1 in toxin-treated cells. In vitro glucosylation was used to determine K(m) and median inhibitory concentration (IC(50)) values. Formation of defensin-toxin complexes was analyzed by precipitation and turbidity studies.
RESULTS: Treatment of cells with human alpha-defensins caused loss of cytotoxicity of toxin B, but not of toxin A. Only alpha-defensins, but not beta-defensin-1 or cathelicidin LL-37, inhibited toxin B-catalyzed in vitro glucosylation of Rho guanosine triphosphatases in a competitive manner, increasing K(m) values for uridine 5'-diphosphate-glucose up to 10-fold. The IC(50) values for inhibition of toxin B-catalyzed glucosylation by the alpha-defensins were 0.6-1.5 micromol/L. At high concentrations, defensins (HNP-1 > or = 2 micromol/L) caused high-molecular-mass aggregates, comparable to Bacillus anthracis protective antigen and lethal factor.
CONCLUSION: Our data indicate that toxin B interacts with high affinity with alpha-defensins and suggest that defensins may provide a defense mechanism against some types of clostridial glucosylating cytotoxins.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18435932     DOI: 10.1053/j.gastro.2008.03.008

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  50 in total

Review 1.  Clostridium difficile in the ICU: the struggle continues.

Authors:  Linda D Bobo; Erik R Dubberke; Marin Kollef
Journal:  Chest       Date:  2011-12       Impact factor: 9.410

2.  Identification of a genetic locus responsible for antimicrobial peptide resistance in Clostridium difficile.

Authors:  Shonna M McBride; Abraham L Sonenshein
Journal:  Infect Immun       Date:  2010-10-25       Impact factor: 3.441

3.  Synergistic effects of antimicrobial peptides and antibiotics against Clostridium difficile.

Authors:  Sabine Nuding; Tina Frasch; Martin Schaller; Eduard F Stange; Lutz T Zabel
Journal:  Antimicrob Agents Chemother       Date:  2014-07-14       Impact factor: 5.191

4.  Current Status of Nonantibiotic and Adjunct Therapies for Clostridium difficile Infection.

Authors:  Nuntra Suwantarat; David A Bobak
Journal:  Curr Infect Dis Rep       Date:  2011-02       Impact factor: 3.725

5.  Good fences make good neighbors: Gastrointestinal mucosal structure.

Authors:  Hannah L Turner; Jerrold R Turner
Journal:  Gut Microbes       Date:  2010-01

6.  Trp-26 imparts functional versatility to human alpha-defensin HNP1.

Authors:  Gang Wei; Marzena Pazgier; Erik de Leeuw; Mohsen Rajabi; Jing Li; Guozhang Zou; Grace Jung; Weirong Yuan; Wei-Yue Lu; Robert I Lehrer; Wuyuan Lu
Journal:  J Biol Chem       Date:  2010-03-10       Impact factor: 5.157

Review 7.  Defensins as anti-inflammatory compounds and mucosal adjuvants.

Authors:  Karl G Kohlgraf; Lindsey C Pingel; Deborah E Dietrich; Kim A Brogden
Journal:  Future Microbiol       Date:  2010-01       Impact factor: 3.165

Review 8.  From stool transplants to next-generation microbiota therapeutics.

Authors:  Elaine O Petrof; Alexander Khoruts
Journal:  Gastroenterology       Date:  2014-01-08       Impact factor: 22.682

9.  Human alpha- and beta-defensins bind to immobilized adhesins from Porphyromonas gingivalis.

Authors:  Deborah E Dietrich; Xiangjun Xiao; Deborah V Dawson; Myriam Bélanger; Hua Xie; Ann Progulske-Fox; Kim A Brogden
Journal:  Infect Immun       Date:  2008-10-13       Impact factor: 3.441

10.  Human alpha-defensins inhibit BK virus infection by aggregating virions and blocking binding to host cells.

Authors:  Aisling S Dugan; Melissa S Maginnis; Joslynn A Jordan; Megan L Gasparovic; Kate Manley; Rebecca Page; Geoffrey Williams; Edith Porter; Bethany A O'Hara; Walter J Atwood
Journal:  J Biol Chem       Date:  2008-09-09       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.